{"id":"W4281719370","doi":"10.1200/jco.2022.40.16_suppl.8018","title":"Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Adverse effect; Multiple myeloma; Clinical endpoint; Oncology; Expanded access; Lenalidomide; Phases of clinical research; Discontinuation; Clinical trial; Surgery; Gastroenterology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003221368,0.0009792527,0.002132368,0.0003372048,0.0003198201,0.0009445327,0.0009919708,0.0008285769,0.002240144],"category_scores_gemma":[0.001318418,0.0006121551,0.001690863,0.0003351858,0.0006216185,0.0008171133,0.0005524921,0.00206309,0.0006979333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001602451,"about_ca_system_score_gemma":0.00161919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009737702,"about_ca_topic_score_gemma":0.002840583,"domain_scores_codex":[0.9989015,0.000608304,0.00006912077,0.0001608084,0.0001363868,0.000124019],"domain_scores_gemma":[0.9989493,0.0001489823,0.0003151751,0.0000816791,0.00006597149,0.0004387942],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7824848,0.03330236,0.04774544,0.001301641,0.004920139,0.000270657,0.0004095059,0.002396284,0.02985993,0.0002115535,0.003892355,0.09320533],"study_design_scores_gemma":[0.3977442,0.4962289,0.08979277,0.00009260205,0.002731481,0.0007105794,0.0001024071,0.001768776,0.003482763,0.0002145472,0.007083152,0.00004785507],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938936,0.002469454,0.0002547654,0.0002052511,0.00003672377,0.0008966393,0.001095838,0.00004538639,0.001102408],"genre_scores_gemma":[0.9927542,0.0008560984,0.0009857393,0.0005249155,0.0001037079,0.0009657813,0.002422124,0.00001430716,0.001373215],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003221368,"threshold_uncertainty_score":0.01703638,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05975955941285862,"score_gpt":0.4140060801500837,"score_spread":0.3542465207372251,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}